Revolution Medicines, Inc. (BMV:RVMD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 747.52B +356.0% |
| Revenue (ttm) | n/a |
| Net Income | -30.90B |
| EPS | -155.88 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Open | 3,433.00 |
| Previous Close | 3,680.00 |
| Day's Range | 3,433.00 - 3,433.00 |
| 52-Week Range | 2,626.00 - 3,680.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
News
Revolution Medicines price target lowered to $264 from $265 at BofA
BofA analyst Alex Stranahan lowered the firm’s price target on Revolution Medicines (RVMD) to $264 from $265 and keeps a Buy rating on the shares as part of a Q3…
RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’
RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particularly the ORR data disclosed for the drug across RAS…
Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy in the G12D subpopulation looks “overdone and misguid...
Revolution selloff on FDA review docs should be bought, says Truist
Truist recommends using today’s selloff in shares of Revolution Medicines (RVMD) as a buying opportunity. The firm attributes the pullback to newly disclosed mutation-level efficacy data in the FDA re...
Revolution trading down after daraxonrasib review docs, says Stifel
Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additional details on response by KRAS mutation. The FDA cauti...
Revolution Medicines price target raised to $259 from $251 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $259 from $251 and keeps an Outperform rating on the shares as part of a broader research note…
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
Propanc Biopharma (PPCB) highlighted new preclinical data for its candidate PRP in pancreatic ductal adenocarcinoma and compared that profile with a clinical standard recently established by Revolutio...
Revolution Medicines price target raised to $240 from $239 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Revolution Medicines (RVMD) to $240 from $239 and keeps a Buy rating on the shares as part of a broader…
Revolution Medicines begins treating patients in RASolute 309 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of Rasonque, a RAS(ON) multi-selective...
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on October 2 at 1 pm. Webcast Link
Revolution Medicines initiated with a Buy at Brookline
Brookline initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $318 price target
Revolution Medicines resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $267 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform...
Revolution Medicines price target raised to $265 from $225 at BofA
BofA raised the firm’s price target on Revolution Medicines (RVMD) to $265 from $225 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past…
Revolution Medicines gets orphan designation for pancreatic cancer treatment
The FDA granted Revolution Medicines (RVMD)’ zoldonrasib orphan designation as a treatment of pancreatic cancer.
Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA
Revolution Medicines (RVMD) announced that the FDA has granted Breakthrough Therapy Designation to Rasonque, the company’s RAS multi-selective inhibitor, for treatment-naive metastatic pancreatic aden...
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
Revolution Medicines initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $255 price target The firm says the companyis the leading RAS-targeted oncology franchise. Revolution is ...
Revolution Medicines price target raised to $230 from $215 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Revolution Medicines (RVMD) to $230 from $215 and keeps a Buy rating on the shares. The raised target accounts for…
New drug shows promise for lung cancer
Revolution Medicines CEO Dr. Mark Goldsmith discusses the clinical trial results from Rasonque on ‘FBN's Wall Street.'
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
NEJM publishes Phase 1/2 clinical data on daraxonrasib
Revolution Medicines (RVMD) “announced that The New England Journal of Medicine has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RA...
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
Revolution Medicines price target raised to $275 from $240 at Needham
Needham raised the firm’s price target on Revolution Medicines (RVMD) to $275 from $240 and keeps a Buy rating on the shares. The firm is updating its model to reflect…
Revolution Medicines price target raised to $265 from $220 at UBS
UBS raised the firm’s price target on Revolution Medicines (RVMD) to $265 from $220 and keeps a Buy rating on the shares.